A Validated RP - HPLC Method for Simulataneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in a Tablet Dosage Form
Rajesh Sharma 1  
,  
 
 
More details
Hide details
1
School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshshila Campus, Khandwa Road, Indore- 452 001, Madhya Pradesh, India
CORRESPONDING AUTHOR
Rajesh Sharma   

School of Pharmacy, Devi Ahilya Vishwavidyalaya, Takshshila Campus, Khandwa Road, Indore- 452 001, Madhya Pradesh, India
Publish date: 2017-10-06
 
Eurasian J Anal Chem 2009;4(3):276–284
KEYWORDS
ABSTRACT
A simple, rapid reversed-phase high performance liquid chromatographic method had been developed and validated for estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form. The estimation was carried out on Luna C18 (25cm x 4.60 mm, particle size 5µm) column with a mixture of acetonitrile: potassium dihydrogen phosphate buffer (pH 3.0 ± 0.05 adjusted with orthophosphoric acid): triethylamine in the ratio of 70:30:0.5(v/v) as mobile phase. UV detection was performed at 260 nm. The method was validated for linearity, accuracy, precision, specificity and sensitivity as per ICH norms. The developed and validated method was successfully used for the quantitative analysis of commercially available dosage form. The retention time was 1.78 and 2.27 min. for emtricitabine and tenofovir disoproxil fumarate respectively and total run time was 4 min. at a flow rate of 1.5 mLmin-1. The calibration curve was linear over the concentration range of 5-50 µgmL-1 for emtricitabine and 5-50 µgmL-1 for tenofovir disoproxil fumarate. The LOD values were 0.015 and 0.039 µgmL-1 and LOQ are 0.045 and 0.117 µgmL-1 for emtricitabine and tenofovir disoproxil fumarate respectively. The high percentage of recovery and low percentage coefficient of variance confirm the suitability of the method for the simultaneous estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form.
 
REFERENCES (19)
1.
Budawari S (2001) The Merck Index, 13th Edition, Merck and Co. Inc. Whitehouse Station. NJ, p 630, 1631-32.
 
2.
Martindale (2002) The Complete Drug Reference, 33 rd Edition, Pharmaceutical Press, London, p 620, 642.
 
3.
Gish R G, Trinh H, Leung N, Chan F K L, Fried M L, Wright T L, Wang C, Anderson J, Mondou E , Snow A, Sorbel J, Rousseau F, Corey L (2005) Safety and antiviral activity of emtricitabine (FTC) for the chronic hepatitis B infection: a two-year study. J Hepatol 43(1): 60-6.
 
4.
Mangoankar K and Desai A (2008) Simultaneous estimation of emtricitabine, tenofovir disoproxil fumarate and efavirenz from tablets by reverse phase highperformance liquid chromatography method. Indian Drugs 45(3): 188-92.
 
5.
Appala N R, Rao V J, Vanitha P K, Mukilteo K and Srinivasu K (2008) Simultaneous estimation of tenofovir disoproxil, emtricitabine and efavirenz in tablet dosage form by RP- HPLC. Orient J Chem 24(2): in press.
 
6.
Raju N A, Begum S (2008) Simultaneous RP-HPLC Method for the Estimation of the Emtricitabine, Tenofovir Disoproxil fumarate and Efavirenz in Tablet Dosage form. Research J Pharm and Tech 1(4):522-25.
 
7.
Shirkhedkar A A, Bhirud C H, Surana S J (2009) Application of UVSpectrophotometric Methods for Estimation of Tenofovir Disoproxil Fumarate in Tablets. Pak J Pharm Sci 22(1): 27-29.
 
8.
Sparidans R W, Crommentuyn K M, Schellens J H, Beijnen J H (2003) LiquidChromatography assay for the antiviral nucleotide analogue tenofovir in plasma using derivitization with chloroacetaldehyde. J Chromatogr B 791: 227-33.
 
9.
Sentenac S, Fernandez C, Thuillier A, Lechat P and Aymard G (2003) Sensitive determination of tenofovir in human plasma samples using reversed-phase liquidchromatography. J Chromatogr B 793(2): 317-24.
 
10.
Kandagal P B, Manjunatha D H, Seetharamappa J and Kalanur S S (2008) RP-HPLC method for the determination of tenofovir in pharmaceutical formulations and spiked human plasma. Anal Lett 41(4): 561-70.
 
11.
Delahunty T, Bushman L, Fletcher C V (2006) Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J Chromatogr B 830: 6-12.
 
12.
Massaki T, Yuichi K, Naoya O, Atsushi H, Kazuhide B, Tsuguhiro K (2007) Determination of plasma tenofovir concentration using a conventional LC-MS method. Biol Pharm Bull 30: 1784-86.
 
13.
King T, Bushman L, Kiser J, Anderson P L, Michelle R, Delahunty T and Fletcher C V (2006) Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromato B 843(2,7): 147-56.
 
14.
Droste J A H, Aarnoutse R E, Burger D M (2007) Determination of Emtricitabine in Human Plasma using HPLC with Fluorometric Detection. J Liq Chromatogr Related Technol 30(18): 2769-78.
 
15.
Unnam S, Bodepudi H, Kottapalli C B (2007) Development and Validation of Stability indicating liquid chromatographic method for determination of emtricitabine and related impurities in drug substances. J Sep Sci 30: 999-1004.
 
16.
Rezk N L , Crutchley R D , Kashuba A D M ( 2005) Simultaneous quantification of emtricitabine and tenofovir in human plasma using high performance liquid chromatography after solid phase extraction. J Chromatogr B 822: 201-8.
 
17.
Gomes N A, Vaidya V V, Pudage A, Joshi S S and Parekh S A (2008) Liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study. J Pharm Biomed Anal 48(3): 918-26.
 
18.
Joshi M, Nikalje A P, Shahed M, Dehghan M (2009) HPTLC method for the simultaneous estimation of emtricitabine and tenofovir in tablet dosage form. Indian J Pharm Sci 71(1): 95-97.
 
19.
International Conference on Harmonization. ICH Harmonised Tripartite Guidelines– Validation of Analytical Procedures: Methodology, (1997) Fed. Regist.
 
eISSN:1306-3057